Scilex Holding (SCLX) Registration filing summary

Company overview and business model

• Focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain.

• Commercial products include ZTlido (lidocaine topical system), ELYXYB (celecoxib oral solution), and GLOPERBA (liquid colchicine).

• Pipeline includes SP-102 (SEMDEXA) for sciatica, SP-103 (high-dose lidocaine patch), and SP-104 (delayed-release naltrexone for fibromyalgia).

• Operates with a patient-first approach, leveraging proprietary delivery technologies and strategic licensing.

Financial performance and metrics

• Net revenue for the nine months ended September 30, 2025 was $25.5M, down from $41.7M in the prior year period.

• Net loss for the nine months ended September 30, 2025 was $327.9M, compared to $66.3M in the prior year period.

• Accumulated deficit as of September 30, 2025 was $888.7M; cash and cash equivalents were $0.9M.

• Recurring losses, negative cash flows, and substantial cumulative net losses raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Proceeds from warrant exercises (if any) will be used for working capital, general corporate purposes, R&D, regulatory, clinical trials, acquisitions, and debt repayment.

• May allocate a significant portion of proceeds to purchase bitcoin, Ethereum, BNB, Doge, or other cryptocurrencies as part of its treasury strategy.

• Proceeds from resale of shares by selling stockholders will not go to the company.